Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis

Anti‐neutrophil cytoplasmic antibody‐associated vasculitides granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare, potentially organ‐ and life‐threatening autoimmune conditions affecting adult and pediatric patients. An open‐label phase II study was conducted to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamois, Candice, Gibiansky, Leonid, Chavanne, Clarisse, Cheu, Melissa, Lehane, Patricia B., Pordeli, Pooneh, Melega, Simone, Gaudreault, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468568/
https://www.ncbi.nlm.nih.gov/pubmed/35765176
http://dx.doi.org/10.1111/cts.13351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468568/
https://www.ncbi.nlm.nih.gov/pubmed/35765176
http://dx.doi.org/10.1111/cts.13351

Ejemplares similares